UMMS Affiliation
Department of Neurology; Gene Therapy Center
Publication Date
2019-09-11
Document Type
Article
Disciplines
Amino Acids, Peptides, and Proteins | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Enzymes and Coenzymes | Genetic Phenomena | Genetics and Genomics | Nervous System Diseases | Therapeutics | Viruses
Abstract
GM1 gangliosidosis is an autosomal recessive neurodegenerative disorder caused by the deficiency of lysosomal gangliosidebeta-galactosidase (beta-gal) and resulting in accumulation of GM1 ganglioside. The disease spectrum ranges from infantile to late onset and is uniformly fatal, with no effective therapy currently available. Although animal models have been useful for understanding disease pathogenesis and exploring therapeutic targets, no relevant human central nervous system (CNS) model system has been available to study its early pathogenic events or test therapies. To develop a model of human GM1 gangliosidosis in the CNS, we employed CRISPR/Cas9 genome editing to target GLB1 exons 2 and 6, common sites for mutations in patients, to create isogenic induced pluripotent stem (iPS) cell lines with lysosomal beta-gal deficiency. We screened for clones with < 5% of parental cell line beta-gal enzyme activity and confirmed GLB1 knockout clones using DNA sequencing. We then generated GLB1 knockout cerebral organoids from one of these GLB1 knockout iPS cell clones. Analysis of GLB1 knockout organoids in culture revealed progressive accumulation of GM1 ganglioside. GLB1 knockout organoids microinjected with AAV9-GLB1 vector showed a significant increase in beta-gal activity and a significant reduction in GM1 ganglioside content compared with AAV9-GFP-injected organoids, demonstrating the efficacy of an AAV9 gene therapy-based approach in GM1 gangliosidosis. This proof-of-concept in a human cerebral organoid model completes the pre-clinical studies to advance to clinical trials using the AAV9-GLB1 vector.
Keywords
4MU, 4-methylumbelliferyl, AAV, adeno-associated virus, AAV9, AAV serotype 9, BSA, bovine serum albumin, CNS, central nervous system, CPB, citrate phosphate buffer, EB, embryoid body, GFP, green fluorescent protein, HPTLC, high-performance thin-layer chromatography, PBS, phosphate-buffered saline, RT-qPCR, real-time quantitative polymerase chain reaction, SD, standard deviation, X-gal, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, hiPSC, human induced pluripotent stem cells, iPS, induced pluripotent stem, β-gal, β-galactosidase
Rights and Permissions
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
DOI of Published Version
10.1016/j.ymgmr.2019.100513
Source
Mol Genet Metab Rep. 2019 Sep 11;21:100513. doi: 10.1016/j.ymgmr.2019.100513. eCollection 2019 Dec. Link to article on publisher's site
Journal/Book/Conference Title
Molecular genetics and metabolism reports
Related Resources
PubMed ID
31534909
Repository Citation
Latour YL, Yoon R, Thomas SE, Grant C, Li C, Sena-Esteves M, Allende ML, Proia RL, Tifft CJ. (2019). Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis. Open Access Articles. https://doi.org/10.1016/j.ymgmr.2019.100513. Retrieved from https://escholarship.umassmed.edu/oapubs/3993
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Included in
Amino Acids, Peptides, and Proteins Commons, Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Enzymes and Coenzymes Commons, Genetic Phenomena Commons, Genetics and Genomics Commons, Nervous System Diseases Commons, Therapeutics Commons, Viruses Commons